Skip to main content
  • CoapTech Receives CE Mark Approval and CPT Procedure Code for Its PUMA-G System

    The UMB med device startup is focused on delivering transformative solutions for minimally-invasive surgery.

    Read more
  • UMB startup Medcura launched a new class of high-performance, antibacterial hemostats

    Rapid-Seal® is available online and through a leading drugstore in the U.S. market.

    Read more
  • COVID-19 Research Operation Updates

    Effective Monday, June 21, 2021 research operations will move a step closer toward normal operations.

    Learn more
  • RNA Disease Diagnostics Licenses Cutting-Edge Molecular RNA Diagnostic Platform Technology

    Developed by Dipanjan Pan, MSc, PhD, and his teams at UMB and UMBC, RNADD plans to use the sensor technology to develop a rapid point-of-care COVID-19 test that is comparable to the gold standard RT-PCR lab diagnostic.

    Read more
  • UM Research Is Top 10 For NSF Higher Education R&D

    With more than $1.1 billion in combined research expenditures, the Baltimore/College Park enterprise placed 14th overall nationally and eighth among all public institutions in Research & Development (R&D) spending.

    Read more
  • Edwards Lifesciences treats first patient with Harpoon System in clinical trial

    The HARPOON system was developed at UMB by James. S. Gammie, MD.

    Learn more
  • First Patients Treated with UMB-developed ECMO Technology

    Developed by UMB startup, Breethe, the device was acquired by Abiomed in October 2020.

    Read the story
  • MissionGO sets new record distance for delivering a human organ

    Co-founded by UMSOM's Dr. Joseph Scalea, MissionGO and its sister company, MediGO, are working to make unmanned aircraft a reliable mode of transportation for life-saving cargo.


    Read more
  • GlycoT Therapeutics Grants Sublicense to Daiichi Sankyo

    The agreement provides worldwide, non-exclusive rights to two pieces of University of Maryland, Baltimore technology as well as two pieces of University of Maryland, College Park technology.

    Read more

Spotlight on...

UM Ventures has launched a series of initiatives for the Center for Maryland Advanced Ventures, including:

NEW ACCELERATOR: Trajectory Next
Trajectory Next is a 12-week post-accelerator program for digital health, bio-health, and life sciences startups.

The Baltimore Fund
The Baltimore Fund provides financial incentives to companies affiliated with Maryland Public Higher Education Institutions to locate in a network of innovation centers in Baltimore City.

The UMCP Fischell Institute
The UMCP Fischell Institute for Biomedical Devices is opening a satellite location at UMB to accelerate the development of innovative medical devices.

Maryland Momentum Fund
The University System of Maryland created the Maryland Momentum Fund, a $25 million early-stage investment program investing in USM-affiliated companies. The Maryland Momentum Fund is staffed by UM Ventures.

University of Maryland, Baltimore Institute for Clinical and Translational Research
The University of Maryland, Baltimore Institute for Clinical and Translational Research (ICTR) is pleased to announce the first round of UMB ICTR Accelerated Translational Incubator Pilot (ATIP) Grant funding opportunities for 2018-2019.


University of Maryland, College Park
University of Maryland, Baltimore

UM Ventures is a joint initiative of the University of Maryland, Baltimore and University of Maryland, College Park to commercialize technologies and expand industry collaboration.

Learn More